Abeona Therapeutics Inc (ABEO)

Etorro trading 970x250
Abeona Therapeutics Inc (ABEO) Logo

About Abeona Therapeutics Inc

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101, an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosis; and ABO-5OX for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. Abeona Therapeutics Inc. has a license agreement with REGENXBIO Inc. for the development and commercialization of gene therapies for the treatment of MPS IIIA, MPS IIIB, CLN1 disease, and CLN3 disease. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York. Address: 1330 Avenue of the Americas, New York, NY, United States, 10019

Abeona Therapeutics Inc News and around…

Latest news about Abeona Therapeutics Inc (ABEO) common stock and company :

Recap: Abeona Therapeutics Q2 Earnings
11 Aug, 2022 FinancialContent

Abeona Therapeutics (NASDAQ:ABEO) reported its Q2 earnings results on Thursday, August 11, 2022 at 07:30 AM. Here's ...

Abeona Therapeutics Reports Second Quarter 2022 Financial Results
11 Aug, 2022 Yahoo! Finance

Disposition of MPS programs allows Abeona to extend runway of current cash into 2Q 2023 Phase 3 VIITAL™ study topline data expected in late-3Q/early-4Q 2022 upon completion of final patient monitoring visit in mid-September Baseline wound characteristics in VIITAL™ reveal significant scope for pain reduction and EB-101 differentiation NEW YORK and CLEVELAND, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announ

12 Health Care Stocks Moving In Thursday's Pre-Market Session
04 Aug, 2022 FinancialContent

Gainers InVivo Therapeutics Hldg (NASDAQ:NVIV) stock increased by 109.5% to $9.26 during Thursday's pre-market ...

Abeona Therapeutics Regains Compliance with Nasdaq Listing Requirements
20 Jul, 2022 Yahoo! Finance

NEW YORK and CLEVELAND, July 20, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) on July 19, 2022 informing Abeona that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on The Nasdaq Capital Market. In order to regain compliance with the Rule, the Company’s common stock was required to maintain a minimum closin

Tesla, Twitter And 76 Biggest Movers From Friday
11 Jul, 2022 FinancialContent

Gainers Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as ...

This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
08 Jul, 2022 FinancialContent

Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the ...

The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
05 Jul, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AstraZeneca Strengthens Its ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
05 Jul, 2022 FinancialContent

Gainers Abeona Therapeutics (NASDAQ:ABEO) stock moved upwards by 1961.6% to $3.95 during Tuesday's pre-market ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
05 Jul, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips It's time to dive into all of the latest stock market news for Tuesday morning as we go over the biggest pre-market stock movers! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace $200 Oil Sooner Than You Think – Buy This Now The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 in savings or $5 million. Do this now.

12 Health Care Stocks Moving In Thursday's After-Market Session
30 Jun, 2022 FinancialContent

Gainers Akebia Therapeutics (NASDAQ:AKBA) stock moved upwards by 39.2% to $0.49 during Thursday's after-market session. Akebia ...

F-star (FSTX) Stock Rises on Buyout Offer From Sino Biopharm
24 Jun, 2022 Yahoo! Finance

Sino Biopharmaceutical, through its wholly-owned subsidiary, is set to acquire F-star (FSTX) for $7.12 per share in cash. The transaction is likely to close by second-half 2022.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
10 Jun, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Good morning, investors! With another day starting comes another breakdown of the biggest pre-market stock movers for Friday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

bluebird (BLUE) Up as FDA Nod Likely for Thalassemia Therapy
08 Jun, 2022 Yahoo! Finance

Based on briefing documents issued by the FDA, a positive regulatory approval is expected on bluebird bio's (BLUE) gene-therapy for treating thalassemia.

AstraZeneca (AZN) Breast Cancer Drug Cuts Risk of Death to Half
06 Jun, 2022 Yahoo! Finance

Data from a late-stage study shows that AstraZeneca's (AZN) Enhertu meets superior and clinically meaningful progression-free survival and overall survival in HER2-low metastatic breast cancer patients.

Abeona Therapeutics to Present at the Jefferies Healthcare Conference
06 Jun, 2022 Yahoo! Finance

NEW YORK and CLEVELAND, June 06, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that company management is scheduled to present at the Jefferies Healthcare Conference on Thursday, June 9, 2022, at 3:30 p.m. EDT. A live webcast of the presentation will be available on the Investors section of the Abeona website under "Events" at https://investors.abeonatherapeutics.com/events. The webcast will be archived for 3

BioMarin (BMRN) Delays FDA Re-Submission for Hemophilia Drug
01 Jun, 2022 Yahoo! Finance

BioMarin (BMRN) posts follow-up data from a phase I/II study on its gene-therapy candidate for hemophilia A. However, the stock falls 7% as management plans to defer the candidate's BLA filing.

Amicus' (FOLD) Galafold Aids Growth, Overdependence a Woe
31 May, 2022 Yahoo! Finance

Currently, Amicus Therapeutics (FOLD) has only one marketed product in its portfolio, the Fabry disease drug Galafold. The FDA is reviewing FOLD's filings that seek approval for Pompe disease.

Aerie (AERI) Starts Late-Stage Study to Treat Dry Eye Disease
25 May, 2022 Yahoo! Finance

Aerie Pharmaceutials (AERI) doses the first patient in a phase III study on its investigational TRMP8 agonist drug for the treatment of dry eye disease.

Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal
23 May, 2022 Yahoo! Finance

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.

Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops
19 May, 2022 Yahoo! Finance

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

Abeona Therapeutics Granted Second 180-Day Period by Nasdaq to Regain Compliance with Minimum Bid Price Rule
19 May, 2022 Yahoo! Finance

NEW YORK and CLEVELAND, May 19, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced that the Company has been granted an additional 180-day period from Nasdaq’s Listing Qualification Department, through November 14, 2022, to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market. The Company's common stock continues to trade on the Nasdaq Capital Market und

AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study
18 May, 2022 Yahoo! Finance

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

Ultragenyx (RARE) Acquires Rights of AAV Gene Therapy Candidate
18 May, 2022 Yahoo! Finance

Ultragenyx (RARE) signs an exclusive license agreement with Abeona Therapeutics to acquire the latter's gene therapy candidate, ABO-102 (now UX111), for treating Sanfilippo syndrome type A.

AbbVie (ABBV) Buys Option Rights to NextGen Inflammation Drug
17 May, 2022 Yahoo! Finance

AbbVie (ABBV) receives the option to license worldwide rights for certain IL-2 muteins, including the next-generation inflammatory candidate, CUG252 from Cugene

The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
17 May, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA May Authorize ...

Ultragenyx Acquires Global Rights to AAV Gene Therapy ABO-102 for Sanfilippo Syndrome Type A (MPS IIIA) from Abeona Therapeutics
17 May, 2022 Yahoo! Finance

ABO-102 / UX111 is being evaluated in ongoing pivotal Transpher A trial in patients with MPS IIIA Interim data featured in encore oral presentation at American Society of Gene & Cell Therapy (ASGCT) today NOVATO, Calif. and NEW YORK and CLEVELAND, May 17, 2022 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced an exclusive license agreement for AAV gene therapy ABO-102 (now UX111) for the treatment of Sanfilippo syndrome

Recap: Abeona Therapeutics Q1 Earnings
13 May, 2022 FinancialContent

Abeona Therapeutics (NASDAQ:ABEO) reported its Q1 earnings results on Friday, May 13, 2022 at 07:30 AM. Here's what ...

Abeona Therapeutics: Q1 Earnings Insights
13 May, 2022 FinancialContent

Abeona Therapeutics (NASDAQ:ABEO) reported its Q1 earnings results on Friday, May 13, 2022 at 07:30 AM. Here's what ...

Abeona Therapeutics Reports First Quarter 2022 Financial Results
13 May, 2022 Yahoo! Finance

Disposition of MPS programs to reduce operating expenses and extend projected cash runway into 2Q 2023 Focus R&D resources on EB-101 pivotal phase 3 VIITAL™ topline data expected in 3Q 2022 NEW YORK and CLEVELAND, May 13, 2022 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in cell and gene therapy, today announced financial results for the first quarter of 2022. The Company will host a conference call and webcast on Tuesday, May 17, 2022, at 8:30 a.m. ET,

AbbVie's (ABBV) Rinvoq Meets Crohn's Disease Study Goals
12 May, 2022 Yahoo! Finance

AbbVie's (ABBV) Rinvoq achieves statistical significance with its co-primary endpoints of clinical remission and endoscopic response in a late-stage study for Crohn's disease.

Abeona Therapeutics Inc (ABEO) is a NASDAQ Common Stock listed in , ,

970x250